Liposomal Chemotherapeutics
Christian Celia, Pharm.D., Ph.D. Department of Pharmacy, University of Chieti – Pescara, “G. d’Annunzio” Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA E-mail: [email protected]; Phone office: +39 0871 355 4711
ITEMS ✔ Introduction to Nanotherapeutics and Nanomedicines ✔ Lipid based Nanotherapeutics in Nanomedicines ✔ Conclusion
✔ Future Perspective
Introduction to Nanotherapeutics
K. Park. Journal of Controlled Release, 2014, 190, 3 – 8.
A. Babu, A.K. Templeton, A. Munshi, R. Ramesh. AAPS PharmSciTech, 2014, 15, 709 – 721.
A. Hafner, J. Lovrić, G.P. Lakoš, I. Pepić, International Journal of Nanomedicine, 2014, 9, 1005 – 1023.
A. Hafner, J. Lovrić, G.P. Lakoš, I. Pepić, International Journal of Nanomedicine, 2014, 9, 1005 – 1023.
A. Hafner, J. Lovrić, G.P. Lakoš, I. Pepić, International Journal of Nanomedicine, 2014, 9, 1005 – 1023.
http://www.slideshare.net/uapnazmul/liposomal-drug-delivery-system
K. Park. ACS Nano, 2013, 7, 7442 – 7447.
Lipid based Nanotherapeutics in Nanomedicines
Anticancer Therapy
A. Babu, A.K. Templeton, A. Munshi, R. Ramesh. AAPS PharmSciTech, 2014, 15, 709 – 721.
C.M. Dawidczyk, C. Kima, J.H. Park, L.M. Russell, K.H. Lee, M.G. Pomper, P.C. Searson, Journal of Controlled Release, 2014, 187, 133 – 144.
V. Sanna, N. Pala, M. Sechi, International Journal of Nanomedicine, 2014, 9, 467 – 483.
E. Gentile, F. Cilurzo, L. Di Marzio, M. Carafa, C.A. Ventura, J. Wolfram, D. Paolino, C. Celia., Future Oncology, 2013, 9, 1849 – 1859.
M.G. Calvagno, C. Celia, D. Paolino, D. Cosco, M. Iannone, F. Castelli, P. Doldo, M. Fresta, Current Drug Delivery 2007, 4, 89 – 101.
C. Celia, E. Trapasso, M. Locatelli, M. Navarra, C.A. Ventura, J. Wolfram, M. Carafa, V.M. Morittu, D. Britti, L. Di Marzio, D. Paolino, Colloids Surf B: Biointerfaces, 2013, 112, 548 – 553.
D. Paolino, D. Cosco, L. Racanicchi, E. Trapasso, C. Celia, M. Iannone, E. Puxeddu, G. Costante, S. Filetti, D. Russo, M. Fresta, Journal of Controlled Release, 2010, 144, 144 – 150.
D. Cosco, A. Bulotta, M. Ventura, C. Celia, T. Calimeri, G. Perri, D. Paolino, N. Costa, P. Neri, P. Tagliaferri, P. Tassone, M. Fresta, Cancer Chemotherapy and Pharmacology, 2009, 64, 1009 – 1020.
E. Gentile, F. Cilurzo, L. Di Marzio, M. Carafa, C.A. Ventura, J. Wolfram, D. Paolino, C. Celia., Future Oncology, 2013, 9, 1849 – 1859.
B.S. Brown, T. Patanam, K. Mobli, C. Celia, P.E. Zage, A.J. Bean, E. Tasciotti, Cancer Biology and Therapy, 2014, 15, 851 – 861.
B.S. Brown, T. Patanam, K. Mobli, C. Celia, P.E. Zage, A.J. Bean, E. Tasciotti, Cancer Biology and Therapy, 2014, 15, 851 – 861.
D. Paolino, D. Cosco, M. Gaspari, M. Celano, J. Wolfram, P. Voce, E. Puxeddu, S. Filetti, C. Celia, M. Ferrari, D. Russo, M. Fresta. Biomaterials, 2014, 35, 7101 – 7109.
D. Paolino, D. Cosco, M. Gaspari, M. Celano, J. Wolfram, P. Voce, E. Puxeddu, S. Filetti, C. Celia, M. Ferrari, D. Russo, M. Fresta. Biomaterials, 2014, 35, 7101 – 7109.
G. Pasut, D. Paolino, C. Celia, A. Mero, A.S. Joseph, J. Wolfram, D. Cosco, O. Sciavon, H. Shen, M. Fresta, Journal of Controlled Release, 2015, 199, 106 – 113.
G. Pasut, D. Paolino, C. Celia, A. Mero, A.S. Joseph, J. Wolfram, D. Cosco, O. Sciavon, H. Shen, M. Fresta, Journal of Controlled Release, 2015, 199, 106 – 113.
a, panel a shows the body distribution of SLs after in vivo injection in liver and blood; b, panel b shows the body distribution of SSL(4)s after in vivo injection in liver and blood.
1 1
G. Pasut, D. Paolino, C. Celia, A. Mero, A.S. Joseph, J. Wolfram, D. Cosco, O. Sciavon, H. Shen, M. Fresta, Journal of Controlled Release, 2015, 199, 106 – 113.
Nude SKID mice bearing MDA-MB-231 breast cancer bone metastasis cells treated by using Dox hydrochloride-loaded SSLs. The anticancer treatment is carried out for 5 weeks. Images are acquired per week. Animals are injected i.v. during the treatment. 5 animals per groups is used during the experiments. Key legends: A) PBS solution (control); B) empty SSLs; C) Doxorubicin hydrochloride; D) Doxorubicin hydrochloride-loaded SSLs. Quantification of tumor development and body weight in Nude SKID mice bearing MDA-MB-231 breast cancer bone metastasis cells treated by using Dox hydrochloride-loaded SSLs. Key legends: (●) PBS buffer solution; (▼) Empty SSLs; (■) Doxorubicin hydrochloride; (®) Doxorubicin hydrochloride-loaded SSLs. 5 animals per groups is used during the experiments.
Celia C, Huang Y, Pasut G, Paolino D, Ferrari M, Fresta M, Shen H. 2015; manuscript in preparation.
Celia C, Huang Y, Pasut G, Paolino D, Ferrari M, Fresta M, Shen H. 2015; manuscript in preparation.
D.K. Kirui, C. Celia, R. Molinaro, S.S. Bansal, D. Cosco, M. Fresta, H. Shen, M. Ferrari, Advanced Healthcare Materials, 2015, 4, 1092 – 1103.
D.K. Kirui, C. Celia, R. Molinaro, S.S. Bansal, D. Cosco, M. Fresta, H. Shen, M. Ferrari, Advanced Healthcare Materials, 2015, 4, 1092 – 1103.
J. Sih, S.S. Bansal, S. Filippini, S. Ferrati, K. Raghuwansi, E. Zabre, E. Nicolov, D. Fine, M. Ferrari, G. Palapattu, A. Grattoni. Analitical Bioanalitical Chemistry, 2013, 405, 1547 – 1557.
D. Fine, A. Grattoni, S. Hosali, A. Ziemys, E. De Rosa, J. Gill, R. Medema, L. Hudson, M. Kojic, M. Milosevic, L. Brousseau III, R. Goodall, M. Ferrari, X. Liu. Lab on Chip, 2010, 10, 3074 – 3083.
C. Celia, S. Ferrati, S. Bansal, A. L. van de Ven, B. Ruozi, E. Zabre, S. Hosali, D. Paolino, M.G. Sarpietro, D. Fine, M. Fresta, M. Ferrari, A. Grattoni. Advanced Healthcare Materials, 2014, 3, 230 – 238.
Conclusion ✔ Liposomes can significantly enhance the anticancer
efficiency of chemotherapeutics for the treatment of solid and blood-borne tumors.
✔ Liposomes can increase the circulation time, decrease side
effects, enhance tumor accumulation and overcome drug resistance of chemotherapeutics.
✔ Liposomes improve pharmacokinetic and biopharmaceutical
features of chemotherapeutics. ✔ Liposomes provide a customized chemotherapy in
innovative Nanomedicine. ✔ Liposomes are therapeutic tools for chemotherapeutic
treatment.
Future Perspective ✔Many more liposomal chemotherapeutics will gain clinical
approval in the near future. ✔Overcome the potential toxicity arising from the presence
of PEG on liposomal surface. ✔Overcome the high production costs in comparison with
conventional cytotoxic agents. ✔ Improve the number of Clinical Trails using liposomal
chemotherapeutics.
✔ Customize Selective Liposomal Chemotherapeutics.
Research Staffs and Collaborators
University of Catanzaro “Magna Græcia”, Italy Prof. Massimo Fresta Prof. Donatella Paolino Prof. Donato Cosco Dr. Felisa Cilurzo Dr. Maria Chiara Cristiano
The Methodist Hospital Research Institute, Houston, TX, USA
Prof. Mauro Ferrari Prof. Paolo Decuzzi Prof. Haifa Shen Prof. Alessandro Grattoni Prof. Rita Serda Prof. Ennio Tasciotti Dr. Aryal Santos Dr. Yi Huang Dr. Shyam Bansal Dr. Silvia Ferrati Dr. Dickson Kirui Dr. Krishna Suri Dr. Joy E Wolfram
University of Chieti- Pescara “G. d’Annunzio”, Italy
Prof. Luisa Di Marzio Prof. Marcello Locatelli Dr. Sara Esposito Dr. Martina Di Francesco Dr. Rosita Primavera
Research Staffs and Collaborators
University of Palermo
Prof. Gaetano Giammona Prof. Gennara Cavallaro Prof. Mariano Licciardi
University of Padua
Prof. Oddone Schiavon Prof. Gianfranco Pasut Dr. Anna Mero
University of Rome “La Sapienza”
Prof. Maria Carafa Prof. Carlotta Marianecci Dr. Federica Rinaldi